Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?

Executive Summary

Merck & Co has triumphed against the odds announcing positive top-line results from the cardiovascular outcomes trial of its CETP inhibitor anacetrapib. But questions remain about the level of benefit and the regulatory prospects.

Advertisement

Related Content

Merck Calls It Quits On Anacetrapib
Merck's Keytruda Claims Market Leadership In First-line Lung Cancer
2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi
DalCor To Develop Failed Roche CETP Inhibitor In Genetic Subgroup
Merck Fails To Win Zetia/Vytorin CV Risk Reduction Claim
Who Suffers From Lilly's Evacetrapib Failure?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099033

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel